Literature DB >> 32304746

A report of three COVID-19 cases with prolonged viral RNA detection in anal swabs.

Y Hu1, L Shen2, Y Yao2, Z Xu3, J Zhou4, H Zhou5.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32304746      PMCID: PMC7159869          DOI: 10.1016/j.cmi.2020.04.010

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


× No keyword cloud information.
To the editor An outbreak of coronavirus disease 2019 (COVID-19), caused by novel coronavirus SARS-CoV-2, started in December 2019 at Wuhan, China [1], and has spread widely in the world. The pattern of human-to-human transmission involves mainly droplet and contact. Aerosol transmission might happen in a confined space with a high concentration of aerosol, according to the 7th edition of diagnosis and treatment recommendations for COVID-19 released by the National Health Commission of China [2]. Although faecal–oral transmission has yet to be confirmed, in the first reported COVID-19 case in the United States Michelle et al. detected viral nucleic acid in a stool specimen by real-time RT-PCR (rRT-PCR) [3]. This indicated the possibility of transmission of virus discharged from the bowel. However, during hospital isolation of this patient, viral nucleic acid in the stool specimen rapidly turned negative as compared to the respiratory samples, indicating a low possibility of community contamination. From January 24–26, 2020, we received three mild COVID-19 cases who had a history of travel to Wuhan in the Deqing People's Hospital, Zhejiang, China (Supplementary Material, Case Description). All the patients came to the hospital because of fever with or without respiratory symptoms, and were isolated for observation and treatment. Nasopharyngeal and anal swabs were collected every 1~3 days for detection of SARS-CoV-2 nucleic acids. Anal swabs were negative in the early illness periods (Fig. 1 ). rRT-PCR was performed using commercial kits (Biogerm, Shanghai, China) according to the manufacturer's instructions. Orf1ab (FAM reporter) and N (VIC reporter) genes of SARS-CoV-2 were detected. Samples were considered to be positive when PCR gave rise to reliable signals (Ct ≤38) for either or both genes (see Supplementary Material).
Fig. 1

Diagram of viral detection, fever, and oseltamivir administration in the three cases. SARS-CoV-2 nucleic acids turned negative in the anal swabs 15 and 5 days later than in the nasopharyngeal swabs in cases 1 and 2, respectively. Illness day represents the patients with clear clinical symptoms such as fever (labelled). The black arrows point to the admission day of each case. Virus nucleic acids were tested by real-time RT-PCR. Ct values are shown as Orf1ab+N genes. Oseltamivir was administered in an oral dose of 75 mg twice daily.

Diagram of viral detection, fever, and oseltamivir administration in the three cases. SARS-CoV-2 nucleic acids turned negative in the anal swabs 15 and 5 days later than in the nasopharyngeal swabs in cases 1 and 2, respectively. Illness day represents the patients with clear clinical symptoms such as fever (labelled). The black arrows point to the admission day of each case. Virus nucleic acids were tested by real-time RT-PCR. Ct values are shown as Orf1ab+N genes. Oseltamivir was administered in an oral dose of 75 mg twice daily. After nucleic acid tests turned negative in the respiratory specimens on illness day 15 in case 1 and illness day 11 in case 2, anal swabs from these two cases (without gastrointestinal symptoms) remained persistently positive by PCR for 5 and 15 days respectively (Fig. 1). Typically, the patients could be released from isolation after the virus tested negative in the respiratory tract by PCR. As described in a retrospective study, in 137 survivors from COVID-19, the median duration of viral shedding detected in respiratory specimens was 20 days from illness onset [4]. Nonetheless, patients with respiratory infection may also shed the virus through stool. The presence in anal swabs or stools of SARS-CoV-2 RNA has been shown in several studies [3,[5], [6], [7]], with a positive rate of 39.3% (11 of 28 patients) [6]. However, RNA detection by PCR does not correlate with the risk of transmission. In a recent Nature paper, the German researchers failed to isolate virus from stool samples despite a high virus RNA concentration in a total of 13 samples from four patients with COVID-19 [7]. There are three possible sources of the viral RNA in the anal swabs: (a) sputum that was swallowed, (b) shed gastrointestinal cells infected with the active virus via an oral route, and (c) anal cells infected with the active virus via direct contact. In this study we could not determine which source applied to these patients or whether the detected viral RNA was from live or dead virus. Until 15th March, 2020, only one study showed that active SARS-CoV-2 virus had been isolated from patients' stool in China (mentioned in a consensus [8], data not published). To date, however, there is no conclusive evidence that SARS-CoV-2 virus can be transmitted via the oral–faecal route. Nonetheless, many coronaviruses can be transmitted in this way [5]. In SARS-CoV- and MERS-CoV-infected patients, intestinal infection was observed at later stages of infection [9,10]. Thus, we need more evidence on whether viral shedding shown by PCR demonstrates that the virus can be transmitted through faeces. This study has been reviewed and approved by the Research Ethics Committee of the Deqing People's Hospital (ref# LL2020-01). The patients gave their consent for publication of clinical details, and written informed consents were obtained.

Author contributions

YH and LS contributed equally to this study.

Transparency declaration

All authors declare no conflicts of interest. This work was supported by funding for COVID-19 from Jiaxing Science and Technology Bureau (2020GZ30001). The research funding was provided to Dr Hua Zhou.
  7 in total

1.  Severe acute respiratory syndrome associated coronavirus is detected in intestinal tissues of fatal cases.

Authors:  Xueying Shi; Encong Gong; Dongxia Gao; Bo Zhang; Jie Zheng; Zifen Gao; Yanfeng Zhong; Wanzhong Zou; Bingquan Wu; Weigang Fang; Songlin Liao; Shenglan Wang; Zhigang Xie; Min Lu; Lin Hou; Haohao Zhong; Hongquan Shao; Ning Li; Congrong Liu; Fei Pei; Jingping Yang; Yuping Wang; Zhihui Han; Xiaohong Shi; Qianying Zhang; Jiangfeng You; Xiang Zhu; Jiang Gu
Journal:  Am J Gastroenterol       Date:  2005-01       Impact factor: 10.864

2.  Detectable 2019-nCoV viral RNA in blood is a strong indicator for the further clinical severity.

Authors:  Weilie Chen; Yun Lan; Xiaozhen Yuan; Xilong Deng; Yueping Li; Xiaoli Cai; Liya Li; Ruiying He; Yizhou Tan; Xizi Deng; Ming Gao; Guofang Tang; Lingzhai Zhao; Jinlin Wang; Qinghong Fan; Chunyan Wen; Yuwei Tong; Yangbo Tang; Fengyu Hu; Feng Li; Xiaoping Tang
Journal:  Emerg Microbes Infect       Date:  2020-02-26       Impact factor: 7.163

3.  First Case of 2019 Novel Coronavirus in the United States.

Authors:  Michelle L Holshue; Chas DeBolt; Scott Lindquist; Kathy H Lofy; John Wiesman; Hollianne Bruce; Christopher Spitters; Keith Ericson; Sara Wilkerson; Ahmet Tural; George Diaz; Amanda Cohn; LeAnne Fox; Anita Patel; Susan I Gerber; Lindsay Kim; Suxiang Tong; Xiaoyan Lu; Steve Lindstrom; Mark A Pallansch; William C Weldon; Holly M Biggs; Timothy M Uyeki; Satish K Pillai
Journal:  N Engl J Med       Date:  2020-01-31       Impact factor: 91.245

4.  Human intestinal tract serves as an alternative infection route for Middle East respiratory syndrome coronavirus.

Authors:  Jie Zhou; Cun Li; Guangyu Zhao; Hin Chu; Dong Wang; Helen Hoi-Ning Yan; Vincent Kwok-Man Poon; Lei Wen; Bosco Ho-Yin Wong; Xiaoyu Zhao; Man Chun Chiu; Dong Yang; Yixin Wang; Rex K H Au-Yeung; Ivy Hau-Yee Chan; Shihui Sun; Jasper Fuk-Woo Chan; Kelvin Kai-Wang To; Ziad A Memish; Victor M Corman; Christian Drosten; Ivan Fan-Ngai Hung; Yusen Zhou; Suet Yi Leung; Kwok-Yung Yuen
Journal:  Sci Adv       Date:  2017-11-15       Impact factor: 14.136

5.  A Novel Coronavirus from Patients with Pneumonia in China, 2019.

Authors:  Na Zhu; Dingyu Zhang; Wenling Wang; Xingwang Li; Bo Yang; Jingdong Song; Xiang Zhao; Baoying Huang; Weifeng Shi; Roujian Lu; Peihua Niu; Faxian Zhan; Xuejun Ma; Dayan Wang; Wenbo Xu; Guizhen Wu; George F Gao; Wenjie Tan
Journal:  N Engl J Med       Date:  2020-01-24       Impact factor: 91.245

6.  Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes.

Authors:  Wei Zhang; Rong-Hui Du; Bei Li; Xiao-Shuang Zheng; Xing-Lou Yang; Ben Hu; Yan-Yi Wang; Geng-Fu Xiao; Bing Yan; Zheng-Li Shi; Peng Zhou
Journal:  Emerg Microbes Infect       Date:  2020-02-17       Impact factor: 7.163

7.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.

Authors:  Fei Zhou; Ting Yu; Ronghui Du; Guohui Fan; Ying Liu; Zhibo Liu; Jie Xiang; Yeming Wang; Bin Song; Xiaoying Gu; Lulu Guan; Yuan Wei; Hui Li; Xudong Wu; Jiuyang Xu; Shengjin Tu; Yi Zhang; Hua Chen; Bin Cao
Journal:  Lancet       Date:  2020-03-11       Impact factor: 79.321

  7 in total
  11 in total

1.  Cautious handling of urine from moderate to severe COVID-19 patients.

Authors:  Hidetoshi Nomoto; Masahiro Ishikane; Daisuke Katagiri; Noriko Kinoshita; Mami Nagashima; Kenji Sadamasu; Kazuhisa Yoshimura; Norio Ohmagari
Journal:  Am J Infect Control       Date:  2020-06-02       Impact factor: 2.918

Review 2.  Towards a sensitive and accurate interpretation of molecular testing for SARS-CoV-2: a rapid review of 264 studies.

Authors:  Kamelia R Stanoeva; Annemiek A van der Eijk; Adam Meijer; Laetitia M Kortbeek; Marion P G Koopmans; Chantal B E M Reusken
Journal:  Euro Surveill       Date:  2021-03

3.  No Evidence of Re-infection or Person-to-Person Transmission in Cured COVID-19 Patients in Guangzhou, a Retrospective Observational Study.

Authors:  Gang Xu; Feng Liu; Min Ye; Jun Zhao; Qing Li; Congrui Feng; Yudong Hu; Yueping Li; Haiyan Shi; Fuchun Zhang; Yuwei Tong; Wei Ma
Journal:  Front Med (Lausanne)       Date:  2020-11-30

4.  Determining the communicable period of SARS-CoV-2: A rapid review of the literature, March to September 2020.

Authors:  Mina Park; Colleen Pawliuk; Tribesty Nguyen; Amanda Griffitt; Linda Dix-Cooper; Nadia Fourik; Martin Dawes
Journal:  Euro Surveill       Date:  2021-04

Review 5.  The Involvement of MicroRNAs in SARS-CoV-2 Infection Comorbid with HIV-Associated Preeclampsia.

Authors:  Tashlen Abel; Jagidesa Moodley; Thajasvarie Naicker
Journal:  Curr Hypertens Rep       Date:  2021-04-13       Impact factor: 5.369

6.  SARS-CoV-2 infection and impact on female genital tract: An untested hypothesis.

Authors:  Eleftherios Vavoulidis; Chrysoula Margioula-Siarkou; Stamatios Petousis; Konstantinos Dinas
Journal:  Med Hypotheses       Date:  2020-08-05       Impact factor: 1.538

7.  Prolonged SARS-CoV-2 RNA detection in anal/rectal swabs and stool specimens in COVID-19 patients after negative conversion in nasopharyngeal RT-PCR test.

Authors:  Vincent Kipkorir; Isaac Cheruiyot; Brian Ngure; Musa Misiani; Jeremiah Munguti
Journal:  J Med Virol       Date:  2020-08-02       Impact factor: 20.693

8.  Anal swab as a potentially optimal specimen for SARS-CoV-2 detection to evaluate hospital discharge of COVID-19 patients.

Authors:  Mei Sun; Dong Guo; Jing Zhang; Jian Zhang; Hai-Feng Teng; Jun Xia; Peng Liu; Quan-Xu Ge; Ming-Yi Wang
Journal:  Future Microbiol       Date:  2020-08-14       Impact factor: 3.165

9.  Incidence, clinical course and risk factor for recurrent PCR positivity in discharged COVID-19 patients in Guangzhou, China: A prospective cohort study.

Authors:  Jiazhen Zheng; Rui Zhou; Fengjuan Chen; Guofang Tang; Keyi Wu; Furong Li; Huamin Liu; Jianyun Lu; Jiyuan Zhou; Ziying Yang; Yuxin Yuan; Chunliang Lei; Xianbo Wu
Journal:  PLoS Negl Trop Dis       Date:  2020-08-31

10.  Systematic review with meta-analysis: SARS-CoV-2 stool testing and the potential for faecal-oral transmission.

Authors:  Amarylle S van Doorn; Berrie Meijer; Chris M A Frampton; Murray L Barclay; Nanne K H de Boer
Journal:  Aliment Pharmacol Ther       Date:  2020-08-27       Impact factor: 9.524

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.